Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $13.1852W HIGH $34.29
Volume
2.44 M
Value Traded
52.37 M
Short % Float
18.3%
-5.46%Week
-19.31%1 Month
-7.09%3 Month
+22.68%6 Month
-3.9%5 Year
-99.17%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.08 B
EPS (TTM)
-3.42
P/E Ratio
-
Ent. Value
1.34 B
Total Shares
113.29 M
Float Shares
106.36 M
Insiders
6.12%
Institutions
119.35%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
VRDN Catalyst Timeline
Dated clinical, regulatory and corporate events for Viridian Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Viridian Therapeutics, Inc.
439Total events
7Upcoming
103Tier-1 (high impact)
2016 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutVRDN-003Clinical Data
Positive topline results from REVEAL-1
thyroid eye diseasesource ↗
◆PDUFA DateVeligrotugApprovedRegulatory Filing
PDUFA target action date set for veligrotug
thyroid eye diseasesource ↗
▲FDA ApprovalVeligrotugApprovedFDA Decision
FDA approval of Lumvoa (veligrotug-vvze) for Thyroid Eye Disease
Thyroid Eye Diseasesource ↗
▲Product LaunchVeligrotugApprovedPost-Market
Launch of Lumvoa (veligrotug-vvze) in the U.S.
Thyroid Eye Diseasesource ↗
▲Product LaunchLumvoaApprovedPost-Market
Commercial launch of Lumvoa in the U.S.
thyroid eye diseasesource ↗
◆FDA ApprovalVeligrotugApprovedFDA Decision
Anticipated U.S. commercial launch in mid-2026 if approved under Priority Review
thyroid eye diseasesource ↗
▼Equity OfferingCorporate
Pricing of upsized concurrent public offerings of 1.75% convertible senior notes due 2032 and common stock with aggregate gross proceeds of $350.0 million
▼Equity OfferingCorporate
Proposed concurrent public offerings of convertible senior notes due 2032, common stock and Series B non-voting convertible preferred stock
▲Topline ReadoutVRDN-003Clinical Data
Positive topline results from Phase 3 REVEAL-2 trial of elegrobart in chronic thyroid eye disease
chronic thyroid eye diseasesource ↗
◆Topline ReadoutVRDN-003Clinical Data
Topline data readout for REVEAL-2 narrowed to Q2 2026
chronic TEDsource ↗
▲Topline ReadoutVRDN-003Clinical Data
Positive topline results from Phase 3 REVEAL-1 trial of elegrobart in active thyroid eye disease
active thyroid eye diseasesource ↗
▲Topline ReadoutVeligrotugApprovedClinical Data
Topline results from REVEAL-1 Phase 3 trial: primary endpoint met with high statistical significance
Thyroid Eye Diseasesource ↗
◆Topline ReadoutVRDN-003Clinical Data
Topline data from REVEAL-1 trial of elegrobart expected next month
thyroid eye diseasesource ↗
▲BLA SubmissionVeligrotugApprovedRegulatory Filing
BLA submission for veligrotug under Priority Review
thyroid eye diseasesource ↗
●EU MAA SubmissionVeligrotugApprovedEx-US Regulatory
MAA submitted to EMA for veligrotug
thyroid eye diseasesource ↗
◆EU MAA SubmissionVeligrotugApprovedEx-US Regulatory
Planned MAA submission to EMA for veligrotug
thyroid eye diseasesource ↗
◆Topline ReadoutVRDN-003Clinical Data
Topline data from REVEAL-1 and REVEAL-2 expected in first half of 2026
active and chronic thyroid eye diseasesource ↗
▲FDA Filing AcceptedVeligrotugApprovedRegulatory Filing
FDA accepted BLA for veligrotug
thyroid eye diseasesource ↗
▲Priority ReviewVeligrotugApprovedRegulatory Filing
Priority Review granted for veligrotug BLA
thyroid eye diseasesource ↗
◆IND SubmissionVRDN-008IND
IND submission for VRDN-008 on track for year-end 2025
autoimmune diseasessource ↗
●BLA SubmissionVeligrotugApprovedRegulatory Filing
BLA submission to FDA for veligrotug in TED
thyroid eye diseasesource ↗
▲Partnership / LicenseVeligrotugApprovedCorporate
Exclusive license agreement with Kissei Pharmaceutical for Japan rights to veligrotug and VRDN-003
thyroid eye diseasesource ↗
▲Partnership / LicenseCorporate
Collaboration and license agreement with Kissei for veligrotug and VRDN-003 in Japan
◆Topline ReadoutVRDN-006Clinical Data
VRDN-006 clinical data in healthy volunteers on track for Q3 2025
autoimmune diseasessource ↗
▲Breakthrough Therapy DesignationVeligrotugApprovedDesignation
Veligrotug received Breakthrough Therapy Designation
thyroid eye diseasesource ↗
▲Full ResultsVeligrotugApprovedClinical Data
Positive long-term durability data from THRIVE: 70% of proptosis responders at week 15 maintained response at week 52
active thyroid eye diseasesource ↗
▲Breakthrough Therapy DesignationVeligrotugApprovedDesignation
Breakthrough Therapy Designation granted for veligrotug
thyroid eye diseasesource ↗
◆Timing GuidanceVeligrotugApprovedPresentation
BLA submission for veligrotug anticipated in second half of 2025
thyroid eye diseasesource ↗
◆Management ChangeCorporate
Appointment of Radhika Tripuraneni, M.D. as Chief Medical Officer
◆First Patient DosedVRDN-006Trial
Healthy volunteer data for VRDN-006 expected in second half of 2025
Autoimmune diseasessource ↗
Past FDA Catalysts and PDUFA Decisions
How VRDN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | VRDN-003 (REVEAL-2) | Phase 3 topline data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D39 / 100
Pipeline Score
$0M
Pipeline Value
$301M
Commercial Value
Richly Valued
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 43%
Small Cap(rank 284 of 658)
Percentile Rank
Viridian Therapeutics, Inc. faces pipeline headwinds (39/100), with 1 assets in development.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026) Revenue $71.1M x 4.2 = $301M
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Veligrotug Small moleculeMarketedNCT05176639 | Thyroid Eye Disease | Phase 3 | COMPLETED | 671 | Mar 27, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every VRDN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| veligrotug BreakthroughPriority | active thyroid eye disease (TED) | Phase 3 | 2025-05-20 | 70% of patients treated with veligrotug in THRIVE who were proptosis responders at week 15 maintained their response at week 52Read More | Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) - 70% of patients treated with veligrotug in THRIVE wRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Tousignant JenniferOfficer (Chief Legal Officer) | Sell | -4,212 | $24.50 | 08/19/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VRDN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 2.3 % (76.9 %) | 123.52 M | 6.72 M | 113.53% ( 3.57 M) |
VRDN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VRDN ranks across every disease it competes in
Competitive Position is a premium feature
See how VRDN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVRDN News
VRDNViridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Viridian Therapeutics, a biotechnology firm, will participate in the Wells Fargo 21st Annual Healthcare Conference. Senior management is scheduled for a fireside chat on September 8, 2026. This event will be accessible via a live webcast, showcasing the company's commitment to transparency and investor engagement.
Read more →VRDN▲ +6.8%on this news
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
Viridian Therapeutics has reported its second-quarter financial results for 2026, highlighting the launch of Lumvoa. The company expresses optimism about early indications from this launch, signaling a pivotal transition into a commercial-stage organization. The report reflects the company's ongoing commitment to developing treatments for autoimmune and rare diseases.
Read more →VRDNViridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
Viridian Therapeutics has received U.S. FDA approval for Lumvoa™ (veligrotug-vvze), a new treatment for Thyroid Eye Disease. This approval marks a significant advancement in the company's efforts to provide effective therapies for patients. The launch of Lumvoa™ is expected to enhance treatment options available to those suffering from this condition.
Read more →VRDNViridian Therapeutics to Participate in Upcoming June Investor Conferences
Viridian Therapeutics is set to participate in several investor conferences scheduled for June. The company aims to engage with investors and provide updates on its ongoing projects and developments. This participation reflects Viridian's commitment to maintaining investor relations and transparency.
Read more →VRDNViridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
Viridian Therapeutics has announced the pricing of its upsized concurrent public offerings, which include 1.75% convertible senior notes due in 2032 and common stock. The aggregate gross proceeds from these offerings are expected to be $350 million. This move is part of the company's strategy to raise capital.
Read more →VRDN▲ +33.4%on this newsshared move
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Viridian Therapeutics has reported its financial results for the first quarter of 2026, highlighting recent advancements. However, specific details about the financial performance and progress were not disclosed in the article. The report appears to focus on the company's ongoing developments in the biopharma sector.
Read more →VRDN▲ +33.4%on this newsshared move
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
Viridian Therapeutics has reported positive topline results from its Phase 3 REVEAL-2 clinical trial for Elegrobart, aimed at treating chronic thyroid eye disease. This outcome suggests a promising advancement in therapeutic options for patients. The results may enhance the company's position in the biopharma market.
Read more →VRDN▲ +33.4%on this newsshared move
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
Viridian Therapeutics has announced proposed concurrent public offerings of convertible senior notes due 2032, common stock, and Series B non-voting convertible preferred stock. This move is part of their strategy to raise capital. Further details regarding the offerings have not been disclosed.
Read more →VRDN▼ -32.3%on this newsshared move
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
Viridian Therapeutics has announced positive topline results from its Phase 3 REVEAL-1 clinical trial for Elegrobart, aimed at treating active thyroid eye disease. This development suggests a significant step forward in the treatment options available for patients suffering from this condition. The results may pave the way for further advancements in therapeutic approaches.
Read more →VRDNViridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Viridian Therapeutics reported significant progress in its pipeline, including a Priority Review for the BLA filing of veligrotug, with a PDUFA date of June 30, 2026. The company is also preparing to release pivotal data for elegrobart next month. Both therapies aim to address thyroid eye disease (TED) and represent potential foundational treatments for patients. Financial results for Q4 and full year 2025 were also disclosed, highlighting the company's ongoing development efforts.
Read more →VRDNViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 8, 2026
Viridian Therapeutics announced the approval of non-qualified stock options for a new employee as part of its inducement grants under Nasdaq Listing Rule 5635(c)(4). The grants, totaling 16,650 shares, will vest over four years. The company is also progressing with its late-stage clinical trials for treatments targeting thyroid eye disease.
Read more →VRDNViridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
Viridian Therapeutics announced that the FDA has accepted its Biologics License Application for veligrotug, a treatment for thyroid eye disease, granting it Priority Review. This designation shortens the review timeline to six months and reflects the drug's potential to significantly improve treatment outcomes. The BLA is supported by positive phase 3 trial data demonstrating robust efficacy and safety.
Read more →VRDNViridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
Viridian Therapeutics reported significant financial results and operational advancements for Q3 2025. They have secured access to up to $889 million through financing transactions, which positions them well for future growth. The company has successfully submitted a BLA for their drug veligrotug, aimed at treating thyroid eye disease, with a planned commercial launch in mid-2026, pending approval. Additionally, the company's trials for VRDN-003 are showing strong enrollment and promising results.
Read more →VRDNViridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
Viridian Therapeutics has reported positive developments in its second-quarter financial results, focusing on its lead candidate, veligrotug, which is on track for a Biologics License Application submission in the second half of 2025. The company announced its Breakthrough Therapy Designation by the FDA for veligrotug, demonstrating its potential to outperform existing treatments. Additionally, Viridian has entered an exclusive licensing agreement with Kissei Pharmaceutical to commercialize veligrotug and another candidate in Japan. The company projects a strong cash position supporting its operational runway into 2027 as clinical trials for its portfolio progress.
Read more →VRDN▲ +6%on this news
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million i
Viridian Therapeutics has entered into a collaboration and license agreement with Kissei Pharmaceutical to develop and commercialize two of its drug candidates, veligrotug and VRDN-003, specifically targeting thyroid eye disease (TED) in Japan. Under the terms, Viridian will receive $70 million upfront, with an additional potential $315 million tied to development and commercial milestones. Kissei will take charge of all development, regulatory, and commercialization efforts in Japan. Both companies aim to quickly advance these promising treatment options to meet the needs of TED patients, leveraging Kissei's expertise in rare diseases.
Read more →VRDN▲ +7.8%on this news
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)
Viridian Therapeutics announced positive long-term durability data from its Phase 3 THRIVE clinical trial for veligrotug, an anti-IGF-1R antibody, aimed at treating active thyroid eye disease (TED). By week 52, 70% of patients who responded positively at week 15 maintained their improvement, reinforcing the drug's clinical profile. The company has received Breakthrough Therapy Designation, enhancing its regulatory pathway, with the Biologics License Application submission anticipated in late 2025 and a potential commercial launch planned for 2026.
Read more →VRDN▼ -8.3%on this news
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
Viridian Therapeutics recently highlighted its achievements and financial results for Q1 2025. The company is progressing toward a Biologics License Application (BLA) submission for veligrotug, anticipated in the second half of 2025, with a projected U.S. launch in 2026. Additionally, the firm is on track to deliver topline data from phase 3 trials for VRDN-003 in 2026 and has a well-established cash position expected to sustain operations through 2027. Furthermore, the recent appointment of Jeff Ajer to the Board of Directors is seen as a positive step toward enhancing commercial capabilities.
Read more →VRDNViridian Therapeutics Appoints Jeff Ajer to its Board of Directors
Viridian Therapeutics has appointed Jeff Ajer to its Board of Directors, bringing over 25 years of experience in commercialization for rare diseases and specialty medicines. Ajer's expertise includes leadership roles at BioMarin Pharmaceutical, where he played a crucial role in launching five brands. The company is currently advancing its promising treatment veligrotug towards BLA submission and has reported positive results from its global phase 3 clinical trials. Additionally, Viridian is focused on enhancing its operations and pipeline through the induction of new personnel.
Read more →VRDNViridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
Viridian Therapeutics recently highlighted its successful progress in 2024, particularly the positive topline data from phase 3 trials for veligrotug in patients with thyroid eye disease. The company has a robust financial position, ensuring cash runway into 2027, and is well-positioned for upcoming Biologics License Applications. Viridian is also advancing its FcRn inhibitor programs, with significant milestones expected in the coming years. Additionally, Radhika Tripuraneni has been appointed as the new Chief Medical Officer, which may enhance clinical development efforts.
Read more →VRDN▲ +20.7%on this news
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease - Veligrotug met all primary and secondary endpoints with high statist
Viridian Therapeutics has announced positive topline results from its Phase 3 THRIVE-2 clinical trial for Veligrotug, showing significant efficacy in treating chronic thyroid eye disease (TED). The treatment met all primary and secondary endpoints, achieving a responder rate of 56% for proptosis and a diplopia complete resolution rate of 32%. With a patient completion rate of 94%, the drug shows a favorable safety profile as well. Viridian plans to submit a Biologics License Application (BLA) for Veligrotug in the second half of 2025, with additional studies for another compound, VRDN-003, also underway.
Read more →About Viridian Therapeutics, Inc.
Headquarters221 CRESCENT STREET, WALTHAM, MA, 02453
BIOPHARMAWATCH ELITE PLUS
Trade the next VRDN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime